GFM
PRAX icon

GF Fund Management’s Praxis Precision Medicines PRAX Stock Holding History

GF Fund Management’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$198K Buy
592
+30
+5% +$9.5K ﹤0.01% 275
2026
Q1 		$181K Buy
562
+72
+15% +$22.3K ﹤0.01% 290
2025
Q4 		$144K Buy
490
+37
+8% +$6.89K ﹤0.01% 317
2025
Q3 		$24K Sell
453
-24
-5% -$1.16K ﹤0.01% 470
2025
Q2 		$20.1K Hold
477
– – ﹤0.01% 503
2025
Q1 		$18.1K Buy
477
+86
+22% +$5.37K ﹤0.01% 513
2024
Q4 		$30.1K Buy
+391
New +$28.3K ﹤0.01% 433

Other funds holding PRAX

JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

GF Fund Management's PRAX Position: Q2 2026 in Review

GF Fund Management increased its Praxis Precision Medicines (PRAX) stake by 5.3% in Q2 2026, buying an estimated $9.5K and bringing the position to 592 shares worth $198K. The position accounts for ﹤0.01% of the portfolio, ranked #275.

GF Fund Management first reported a position in PRAX in Q4 2024 and has held it in 7 quarters since. 310 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

  • GF Fund Management held 592 shares of Praxis Precision Medicines worth $198K as of Q2 2026.
  • GF Fund Management bought 30 Praxis Precision Medicines shares in Q2 2026, an estimated $9.5K.
  • Praxis Precision Medicines made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #275 holding.
  • GF Fund Management first reported a position in Praxis Precision Medicines in Q4 2024 and has held it in 7 quarters since.
  • 310 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.